Guardians at the gate: Patent protection for therapeutic monoclonal antibodies - Part 1

mAbs

Volumn 1, Issue 4, 2009, Pages 382-384

  McCabe, Kevin W ^a  

^a Sterne Kessler Goldstein and Fox PLLC   (United States)

Author keywords

KSR; Life cycle management; Monoclonal antibodies; Patent; Therapeutic

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY;

BIOTECHNOLOGY; LAW; PATENT; REVIEW; UNITED STATES;

EID: 77953661237     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.4.8860     Document Type: Review

References (24)

1. 35 U.S.C. § 271.
2. 35 U.S.C. § 2.
3. 35 U.S.C. § 102.
4. 35 U.S.C. § 102(a) and (b).
5. 35 U.S.C. § 103.
6. KSR International Co., v. Teleflex Inc., 550 U.S. -. 127 S.Ct. 1727, 82 U.S.P.Q.2d 1385 (2007).
7. 127 S. Ct. at 1742.
8. 127 S. Ct. at 1742.
9. 127 S. Ct. at 1740-1741
10. 127 S. Ct. at 1741.
11. 127 S. Ct. at 1742.
12. In re Kubin, Slip Opinion dated April 3, 2009, No.2008-1184 (Fed. Cir. April 3, 2009).
13. In re Kubin, Slip Opinion at 4.
14. In re Kubin, Slip Opinion at 12, quoting In re Deuel, 51 F.3d 1552, 1559 (Fed. Cir. 1995).
15. In re Kubin, Slip Opinion at 18.
16. See Eisenberg, Is your application ready under KSR?, IP360 (March 11, 2009).
17. 35 U.S.C. § 112, first paragraph.
18. At least one commentator has noted the similarities between the Wands factors and the Capon factors. Goldstein and Coblentz, Intellectual Property Today at 10-11 (August 2008).
19. In re Wands, 858 F.2d 731 (Fed. Cir. 1988); Capon v. Eshhar, 418 F.3d 1349 (Fed. Cir. 2005).
20. Vas-Cath Inc., v. Mahurkar, 935 F.2d 1555, 1563 (Fed. Cir. 1991).
21. Capon, 418 F.3d at 1351-1352
22. Capon, 418 F.3d at 1357-1359.
23. Capon, 418 F.3d at 1361.
24. In re Wands, 858 F.2d at 737.